Overview

Fraction Dose Escalation of Split-course Adaptive Hypo-fractionated Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This prospective phase I study intends to explore the maximum tolerable single radiation dose for locally advanced non-small cell lung cancer patients undergoing radical concurrent radiochemotherapy at the same bioequivalent radiation dose
Phase:
Phase 1
Details
Lead Sponsor:
Sun Yat-sen University